High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders
作者:Xiaoyu Peng、Yang Li、Junfeng Qu、Lizhi Jiang、Kaiyue Wu、Dan Liu、Yuping Chen、Junmei Peng、Yu Guo、Xuan Cao
DOI:10.1016/j.ejmech.2024.116405
日期:2024.5
toxicity of PARPi, many novel methods have been developed including PROTACs. Being an event-driven technology, PROTACs needs a high affinity, low toxicity warhead with no steric hindrance in binding process. Veliparib shows the lowest PARP-Trapping effect but could hardly to be the warhead of PROTACs because of the strong steric hindrance. Other PARP1 inhibitors showed less steric hindrance but owns high
PARPi已被探索并应用于治疗多种癌症,效果显着,特别是BRCA1/2突变的卵巢癌、乳腺癌、前列腺癌和胰腺癌。然而,由于PARP-Trapping和长期的临床跟踪,PARPi不可避免地产生耐药性并表现出高毒性。为了克服 PARPi 的耐药性和高毒性,人们开发了许多新方法,包括 PROTAC。作为一种事件驱动技术,PROTAC 需要高亲和力、低毒性的弹头,并且在结合过程中没有空间位阻。 Veliparib显示出最低的PARP捕获效果,但由于强烈的空间位阻,很难成为PROTAC的弹头。其他 PARP1 抑制剂表现出较小的空间位阻,但具有较高的 PARP 捕获效果。因此,开发具有高PARP1亲和力、低PARP1捕获且无空间位阻的新型弹头将是有价值的。在这项工作中,我们保留苯并咪唑作为基序以保留低PARP1捕获效应,并用芳环取代吡咯以避免PARP1结合洞中的空间位阻。因此,设计并合成了一系列苯并咪